Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 381

1.

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.

Ducreux M, Petersen LN, Öhler L, Bergamo F, Metges JP, de Groot JW, Wang JY, García Paredes B, Dochy E, Fiala-Buskies S, Cervantes A, O'Connor JM, Falcone A; CORRELATE Investigators.

Eur J Cancer. 2019 Nov 4;123:146-154. doi: 10.1016/j.ejca.2019.09.015. [Epub ahead of print]

2.

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).

Bendell JC, Sauri T, Gracián AC, Alvarez R, López-López C, García-Alfonso P, Hussein M, Miron ML, Cervantes A, Montagut C, Vivas CS, Bessudo A, Plezia P, Moons V, Andel J, Bennouna J, van der Westhuizen A, Samuel L, Rossomanno S, Boetsch C, Lahr A, Franjkovic I, Heil F, Lechner K, Krieter O, Hurwitz H; McCAVE Study Group.

Oncologist. 2019 Sep 30. pii: theoncologist.2019-0291. doi: 10.1634/theoncologist.2019-0291. [Epub ahead of print]

PMID:
31570519
3.

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.

Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, Ferrer-Martínez A, Bruixola G, Fleitas T, Martín J, Tébar-Martínez R, Moro D, Castillo J, Espí A, Roda D, Cervantes A.

Ann Oncol. 2019 Sep 28. pii: mdz390. doi: 10.1093/annonc/mdz390. [Epub ahead of print]

PMID:
31562764
4.

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer.

Cardone C, Martinelli E, Troiani T, Sforza V, Avallone A, Nappi A, Montesarchio V, Andreozzi F, Biglietto M, Calabrese F, Bordonaro R, Cordio S, Bregni G, Febbraro A, Garcia-Carbonero R, Feliu J, Cervantes A, Ciardiello F.

ESMO Open. 2019 Aug 16;4(4):e000519. doi: 10.1136/esmoopen-2019-000519. eCollection 2019.

5.

"Brazilian Butt Lift" Performed by Board-Certified Brazilian Plastic Surgeons: Reports of an Expert Opinion Survey.

Cansancao AL, Condé-Green A, Gouvea Rosique R, Junqueira Rosique M, Cervantes A.

Plast Reconstr Surg. 2019 Sep;144(3):601-609. doi: 10.1097/PRS.0000000000006020.

PMID:
31461012
6.

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper.

Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes A, Chiloiro G, Coco C, Gambacorta MA, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, Rödel C, Rutten H, van de Velde C, Aristei C.

Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)32980-9. doi: 10.1016/j.radonc.2019.07.001. [Epub ahead of print]

PMID:
31431374
7.

In the literature: August 2018.

Gambardella V, Bruixola G, Papaccio F, Cejalvo JM, Cervantes A.

ESMO Open. 2019 Jul 21;4(4):e000563. doi: 10.1136/esmoopen-2019-000563. eCollection 2019. No abstract available.

8.

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.

Cejalvo JM, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Taus Garcia A, Leighl N, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

ESMO Open. 2019 Jul 22;4(4):e000532. doi: 10.1136/esmoopen-2019-000532. eCollection 2019.

9.

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, Martinelli E.

Ann Oncol. 2019 Aug 5. pii: mdz233. doi: 10.1093/annonc/mdz233. [Epub ahead of print] No abstract available.

PMID:
31378807
10.

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.

Abramson VG, Oliveira M, Cervantes A, Wildiers H, Patel MR, Bauer TM, Bedard PL, Becerra C, Richey S, Wei MC, Reyner E, Bond J, Cui N, Wilson TR, Moore HM, Saura C, Krop IE.

Breast Cancer Res Treat. 2019 Nov;178(1):121-133. doi: 10.1007/s10549-019-05360-3. Epub 2019 Jul 31.

PMID:
31368034
11.

Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty.

Lordick F, Obermannova R, Vola D, Douillard JY, Mcgregor K, Van Cutsem E, Tabernero J, Ciardiello F, Cervantes A.

ESMO Open. 2019 Jul 5;4(3):e000533. doi: 10.1136/esmoopen-2019-000533. eCollection 2019. Review.

12.

Serum lipid profile as a biomarker of intra-pancreatic fat deposition: A nested cross-sectional study.

Singh RG, Nguyen NN, Cervantes A, Cho J, Petrov MS.

Nutr Metab Cardiovasc Dis. 2019 Sep;29(9):956-964. doi: 10.1016/j.numecd.2019.06.003. Epub 2019 Jun 14.

PMID:
31353204
13.

Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations.

Roda D, Roselló S, Cervantes A.

Ann Oncol. 2019 Sep 1;30(9):1409-1410. doi: 10.1093/annonc/mdz229. No abstract available.

PMID:
31350557
14.

In the literature: June 2019.

Lamarca A, Gambardella V, Cejalvo JM, Fleitas-Kanonnikoff T, Cervantes A.

ESMO Open. 2019 Jun 20;4(3):e000547. doi: 10.1136/esmoopen-2019-000547. eCollection 2019. No abstract available.

15.

Circulating levels of lipocalin-2 are associated with fatty pancreas but not fatty liver.

Singh RG, Nguyen NN, Cervantes A, Kim JU, Stuart CE, Petrov MS.

Peptides. 2019 Sep;119:170117. doi: 10.1016/j.peptides.2019.170117. Epub 2019 Jul 2.

PMID:
31276730
16.

Brazilian butt lift performed by board certified Brazilian plastic surgeons: Reports of an expert opinion survey.

Cansancao AL, Condé-Green A, Gouvea Rosique R, Junqueira Rosique M, Cervantes A.

Plast Reconstr Surg. 2019 Jun 27. doi: 10.1097/PRS.0000000000006020. [Epub ahead of print]

PMID:
31261264
17.

ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer.

Gimeno-Valiente F, Riffo-Campos ÁL, Vallet-Sánchez A, Siscar-Lewin S, Gambardella V, Tarazona N, Cervantes A, Franco L, Castillo J, López-Rodas G.

Sci Rep. 2019 Jun 27;9(1):9339. doi: 10.1038/s41598-019-45411-9.

18.

Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications.

Martinez-Ciarpaglini C, Fleitas-Kanonnikoff T, Gambardella V, Llorca M, Mongort C, Mengual R, Nieto G, Navarro L, Huerta M, Rosello S, Roda D, Tarazona N, Navarro S, Ribas G, Cervantes A.

ESMO Open. 2019 May 27;4(3):e000470. doi: 10.1136/esmoopen-2018-000470. eCollection 2019.

19.

In the literature: April 2019.

Bruxiola G, Cejalvo JM, Gambardella V, Cervantes A.

ESMO Open. 2019 Apr 20;4(2):e000513. doi: 10.1136/esmoopen-2019-000513. eCollection 2019. No abstract available.

20.

A Central Region of NF-κB Essential Modulator Is Required for IKKβ-Induced Conformational Change and for Signal Propagation.

Shaffer R, DeMaria AM, Kagermazova L, Liu Y, Babaei M, Caban-Penix S, Cervantes A, Jehle S, Makowski L, Gilmore TD, Whitty A, Allen KN.

Biochemistry. 2019 Jul 2;58(26):2906-2920. doi: 10.1021/acs.biochem.8b01316. Epub 2019 Jun 18.

PMID:
31145594
21.

Relationship of Anthropometric Indices to Abdominal Body Composition: A Multi-Ethnic New Zealand Magnetic Resonance Imaging Study.

Cervantes A, Singh RG, Kim JU, DeSouza SV, Petrov MS.

J Clin Med Res. 2019 Jun;11(6):435-446. doi: 10.14740/jocmr3820. Epub 2019 May 10.

22.

Corrigendum to Preclinical models for precision oncology. BBACAN 1870/2 (2018) 239-246.

Ibarrola-Villava M, Cervantes A, Bardelli A.

Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2). pii: S0304-419X(19)30082-4. doi: 10.1016/j.bbcan.2019.05.002. Epub 2019 May 25. No abstract available.

PMID:
31138435
23.

Liver disease in pregnancy: Medical aspects and their implications for mother and child.

García-Romero CS, Guzman C, Cervantes A, Cerbón M.

Ann Hepatol. 2019 Jul - Aug;18(4):553-562. doi: 10.1016/j.aohep.2019.04.009. Epub 2019 May 6. Review.

24.

Niemann-Pick disease A or B in four pediatric patients and SMPD1 mutation carrier frequency in the Mexican population.

Cerón-Rodríguez M, Vázquez-Martínez ER, García-Delgado C, Ortega-Vázquez A, Valencia-Mayoral P, Ramírez-Devars L, Arias-Villegas C, Monroy-Muñoz IE, López M, Cervantes A, Cerbón M, Morán-Barroso VF.

Ann Hepatol. 2019 Jul - Aug;18(4):613-619. doi: 10.1016/j.aohep.2018.12.004. Epub 2019 May 12.

25.

Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes.

Ragulan C, Eason K, Fontana E, Nyamundanda G, Tarazona N, Patil Y, Poudel P, Lawlor RT, Del Rio M, Koo SL, Tan WS, Sclafani F, Begum R, Teixeira Mendes LS, Martineau P, Scarpa A, Cervantes A, Tan IB, Cunningham D, Sadanandam A.

Sci Rep. 2019 May 21;9(1):7665. doi: 10.1038/s41598-019-43492-0.

26.

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Sci Rep. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z.

27.

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.

Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, Spira A, Gonzalez M, Zhong B, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J, Tabernero J.

Clin Cancer Res. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. Epub 2019 May 14.

PMID:
31088831
28.

Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens.

Martinez-Ciarpaglini C, Fernandez-Sellers C, Tarazona N, Roselló S, Huerta M, Roda D, Mongort C, Ferrández A, Navarro S, Cervantes A.

Histopathology. 2019 Oct;75(4):517-525. doi: 10.1111/his.13900. Epub 2019 Aug 7.

PMID:
31081121
29.

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy.

Fleitas-Kanonnikoff T, Martinez-Ciarpaglini C, Ayala J, Gauna C, Denis R, Yoffe I, Sforza S, Martínez MT, Pomata A, Ibarrola-Villava M, Arevshatyan S, Burriel V, Boscá D, Pastor O, Ferrer-Martinez A, Carrasco F, Mongort C, Navarro S, Ribas G, Cervantes A.

Cancer Med. 2019 Jun;8(6):3120-3130. doi: 10.1002/cam4.2191. Epub 2019 May 6.

30.

Associations between intra-pancreatic fat deposition and circulating levels of cytokines.

Singh RG, Nguyen NN, Cervantes A, Alarcon Ramos GC, Cho J, Petrov MS.

Cytokine. 2019 Aug;120:107-114. doi: 10.1016/j.cyto.2019.04.011. Epub 2019 May 1.

PMID:
31054479
31.

Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma.

Gambardella V, Fleitas T, Tarazona N, Cejalvo JM, Gimeno-Valiente F, Martinez-Ciarpaglini C, Huerta M, Roselló S, Castillo J, Roda D, Cervantes A.

Ann Oncol. 2019 May 2. pii: mdz143. doi: 10.1093/annonc/mdz143. [Epub ahead of print]

PMID:
31046106
32.

"Alguien abrió la puerta:" The phenomenology of bilingual Latinx clients' use of Spanish and English in psychotherapy.

Pérez-Rojas AE, Brown R, Cervantes A, Valente T, Pereira SR.

Psychotherapy (Chic). 2019 Jun;56(2):241-253. doi: 10.1037/pst0000224. Epub 2019 Apr 18.

PMID:
30998036
33.

Definition of the Rectum: An International, Expert-based Delphi Consensus.

DʼSouza N, de Neree Tot Babberich MPM, d'Hoore A, Tiret E, Xynos E, Beets-Tan RGH, Nagtegaal ID, Blomqvist L, Holm T, Glimelius B, Lacy A, Cervantes A, Glynne-Jones R, West NP, Perez RO, Quadros C, Lee KY, Madiba TE, Wexner SD, Garcia-Aguilar J, Sahani D, Moran B, Tekkis P, Rutten HJ, Tanis PJ, Wiggers T, Brown G.

Ann Surg. 2019 Apr 8. doi: 10.1097/SLA.0000000000003251. [Epub ahead of print]

PMID:
30973385
34.

In the literature: February 2019.

Insa A, Gambardella V, Cervantes A.

ESMO Open. 2019 Feb 13;4(1):e000490. doi: 10.1136/esmoopen-2019-000490. eCollection 2019. No abstract available.

35.

Intrapancreatic fat deposition and visceral fat volume are associated with the presence of diabetes after acute pancreatitis.

Singh RG, Cervantes A, Kim JU, Nguyen NN, DeSouza SV, Dokpuang D, Lu J, Petrov MS.

Am J Physiol Gastrointest Liver Physiol. 2019 Jun 1;316(6):G806-G815. doi: 10.1152/ajpgi.00385.2018. Epub 2019 Mar 28.

PMID:
30920289
36.

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.

Argilés G, André T, Hollebecque A, Calvo A, Dahan L, Cervantes A, Leger C, Amellal N, Fougeray R, Tabernero J.

Eur J Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. Epub 2019 Mar 16.

PMID:
30889492
37.

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer.

Baguena G, Pellino G, Frasson M, Roselló S, Cervantes A, García-Granero A, Giner F, García-Granero E.

Dis Colon Rectum. 2019 Jun;62(6):684-693. doi: 10.1097/DCR.0000000000001367.

PMID:
30839315
38.

Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline.

Lopes G, Stern MC, Temin S, Sharara AI, Cervantes A, Costas-Chavarri A, Engineer R, Hamashima C, Ho GF, Huitzil FD, Moghani MM, Nandakumar G, Shah MA, Teh C, Manjarrez SEV, Verjee A, Yantiss R, Correa MC.

J Glob Oncol. 2019 Feb;5:1-22. doi: 10.1200/JGO.18.00213.

39.

Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline.

Costas-Chavarri A, Nandakumar G, Temin S, Lopes G, Cervantes A, Cruz Correa M, Engineer R, Hamashima C, Ho GF, Huitzil FD, Malekzadeh Moghani M, Sharara AI, Stern MC, Teh C, Vázquez Manjarrez SE, Verjee A, Yantiss R, Shah MA.

J Glob Oncol. 2019 Feb;5:1-19. doi: 10.1200/JGO.18.00214.

40.

Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials.

Fontana E, Eason K, Cervantes A, Salazar R, Sadanandam A.

Ann Oncol. 2019 Apr 1;30(4):520-527. doi: 10.1093/annonc/mdz052.

41.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Sci Rep. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. Erratum in: Sci Rep. 2019 May 17;9(1):7706.

42.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.

PMID:
30770348
43.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E.

Ann Oncol. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. No abstract available.

PMID:
30715202
44.

A Comparison of Machine Learning and Deep Learning Techniques for Activity Recognition using Mobile Devices.

Baldominos A, Cervantes A, Saez Y, Isasi P.

Sensors (Basel). 2019 Jan 26;19(3). pii: E521. doi: 10.3390/s19030521.

45.

Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cancer.

Gambardella V, Fleitas T, Cervantes A.

Ann Oncol. 2019 Mar 1;30(3):351-352. doi: 10.1093/annonc/mdz008. No abstract available.

PMID:
30657856
46.

Gut Hormone Responses to Mixed Meal Test in New-Onset Prediabetes/Diabetes After Acute Pancreatitis.

Pendharkar SA, Singh RG, Cervantes A, DeSouza SV, Bharmal SH, Petrov MS.

Horm Metab Res. 2019 Mar;51(3):191-199. doi: 10.1055/a-0802-9569. Epub 2018 Dec 20.

PMID:
30572349
47.

In the literature: December 2018.

Gambardella V, Fleitas T, Cervantes A.

ESMO Open. 2018 Nov 28;3(7):e000468. doi: 10.1136/esmoopen-2018-000468. eCollection 2018. No abstract available.

48.

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.

Gambardella V, Gimeno-Valiente F, Tarazona N, Martinez-Ciarpaglini C, Roda D, Fleitas T, Tolosa P, Cejalvo JM, Huerta M, Roselló S, Castillo J, Cervantes A.

Clin Cancer Res. 2019 Mar 1;25(5):1639-1649. doi: 10.1158/1078-0432.CCR-18-2421. Epub 2018 Nov 30.

PMID:
30504425
49.

Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer.

Roselló S, Borrás R, Cervantes A.

Hepatobiliary Surg Nutr. 2018 Oct;7(5):395-398. doi: 10.21037/hbsn.2018.08.02. No abstract available.

50.

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.

González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators.

Gynecol Oncol. 2019 Jan;152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. Epub 2018 Nov 16.

Supplemental Content

Loading ...
Support Center